## 1,1,3,3-Tetramethoxypropane: A Versatile Building Block
**1,1,3,3-Tetramethoxypropane (TMOP)** is a synthetic organic compound with the formula CH3OCH2CH2CH2OCH3. It's a colorless liquid with a slightly sweet odor.
**Importance in Research:**
TMOP is a valuable reagent and building block in organic synthesis due to its several unique properties:
* **Versatile functionality:** The two methoxy groups on each end of the molecule provide a handle for introducing various functional groups through reactions like:
* **Hydrolysis:** TMOP can be hydrolyzed to produce 1,3-propanediol, a valuable precursor for polymers and pharmaceuticals.
* **Dehydration:** TMOP can be dehydrated to form 1,3-dioxolane, another useful building block for organic synthesis.
* **Alkylation:** TMOP can be alkylated to produce various ether derivatives.
* **Protection of aldehydes and ketones:** TMOP can be used to protect aldehydes and ketones in organic reactions by forming a cyclic acetal.
* **Synthesis of complex molecules:** TMOP has been used in the synthesis of various natural products, such as steroids, alkaloids, and terpenoids.
* **Polymerization:** TMOP can be used as a monomer to produce polyesters, polyurethanes, and other polymers with unique properties.
* **Fuel additive:** TMOP has been investigated as a potential fuel additive due to its high oxygen content and good combustion properties.
**Research Applications:**
TMOP is used in a wide variety of research areas, including:
* **Medicinal chemistry:** TMOP has been used in the development of new drugs for treating a variety of diseases, including cancer, infections, and neurological disorders.
* **Materials science:** TMOP is being investigated as a component of new materials with improved properties, such as strength, flexibility, and conductivity.
* **Environmental chemistry:** TMOP has been used to study the degradation of pollutants in the environment.
**Safety Concerns:**
While TMOP is a valuable research tool, it is important to handle it with care. It is flammable and can cause irritation to the skin, eyes, and respiratory system.
**In summary, 1,1,3,3-tetramethoxypropane is a versatile building block in organic chemistry with numerous applications in various research fields. Its unique properties and reactivity make it a valuable reagent for the synthesis of complex molecules, the protection of functional groups, and the development of new materials.**
| ID Source | ID |
|---|---|
| PubMed CID | 66019 |
| CHEMBL ID | 592723 |
| SCHEMBL ID | 9106 |
| MeSH ID | M0122543 |
| Synonym |
|---|
| LS-13384 |
| 1,3,3-tetramethoxypropane |
| malonaldehyde bis(dimethyl acetal) |
| malonaldehyde tetramethyl acetal |
| 102-52-3 |
| tetramethoxypropane |
| propane,1,3,3-tetramethoxy- |
| nsc27794 |
| malonaldehyde, bis(dimethyl acetal) |
| nsc-27794 |
| 1,1,3,3-tetramethoxy-propane |
| propane, 1,1,3,3-tetramethoxy- |
| 1,1,3,3-tetramethoxypropane , |
| inchi=1/c7h16o4/c1-8-6(9-2)5-7(10-3)11-4/h6-7h,5h2,1-4h3 |
| xhtyqfmrbqucpx-uhfffaoysa- |
| 1,1,3,3-tetramethoxypropane, 99% |
| 1,1,3,3,-tetramethoxypropane |
| CHEMBL592723 |
| M0544 |
| AKOS000119925 |
| A800582 |
| T2833 |
| ai3-28938 |
| gub3d2sv2s , |
| nsc 27794 |
| unii-gub3d2sv2s |
| einecs 203-037-2 |
| FT-0606001 |
| BP-30166 |
| SCHEMBL9106 |
| DTXSID4059255 |
| 1,1,3,3-tetrakis(methyloxy)propane |
| 1,1,3,3-tetramethoxy propane |
| malonaldehyde bis (dimethyl acetal) |
| malondialdehyde bis(dimethylacetal) |
| Q-200045 |
| malonaldehyde bis(dimethyl acetal |
| mfcd00008488 |
| 1,1,3,3-tetramethoxypropane, 97% |
| F0001-0070 |
| E76642 |
| malondialdehyde tetramethyl acetal |
| STL185615 |
| malonaldehyde bis-(dimethyl acetal) |
| BP-31195 |
| CS-W020634 |
| EN300-19218 |
| Z104473196 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID462859 | Analgesic activity in ICR mouse assessed as increase in pain threshold variation at 20 umol/kg, po administered as single dose measured after 120 mins by tail flick test | 2010 | Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6 | A class of novel Schiff's bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis. |
| AID462865 | Analgesic activity in ICR mouse assessed as increase in pain threshold variation at 20 umol/kg, po administered as single dose measured after 180 mins by tail flick test | 2010 | Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6 | A class of novel Schiff's bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis. |
| AID462862 | Analgesic activity in ICR mouse assessed as increase in pain threshold variation at 20 umol/kg, po administered as single dose measured after 150 mins by tail flick test | 2010 | Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6 | A class of novel Schiff's bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis. |
| AID462851 | Analgesic activity in ICR mouse assessed as increase in pain threshold variation at 20 umol/kg, po administered as single dose measured after 30 mins by tail flick test | 2010 | Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6 | A class of novel Schiff's bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis. |
| AID462856 | Analgesic activity in ICR mouse assessed as increase in pain threshold variation at 20 umol/kg, po administered as single dose measured after 90 mins by tail flick test | 2010 | Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6 | A class of novel Schiff's bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis. |
| AID462853 | Analgesic activity in ICR mouse assessed as increase in pain threshold variation at 20 umol/kg, po administered as single dose measured after 60 mins by tail flick test | 2010 | Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6 | A class of novel Schiff's bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||